Key facts
- Manuals
- 1
- Languages
- ZH
- Last added
- 2026-10-03
Featured ERLEADA manuals
ERLEADA Apalutamide Product Information Sheet
ERLEADA® is prescribed as a 240 mg oral tablet taken once daily, either with or without food. The tablet contains 60 mg of apalutamide per pill and may be reduced to 180 mg or 120 mg if toxicity of grade 3 or higher occurs.
The drug is indicated for adult men with metastatic castration‑sensitive prostate cancer (mCSPC) and high‑risk non‑metastatic castration‑resistant prostate cancer (nmCRPC). Reimbursement requires prior approval, pathology reports, and regular PSA monitoring. Common adverse reactions include rash, which should be managed with topical steroids or antihistamines and may require temporary discontinuation. This manual is written in Chinese.
Covers: Product Name · Generic Name · Dosage and Administration · Indications · Reimbursement Guidelines · Drug Overview
Latest ERLEADA manuals
ERLEADA Apalutamide Product Information Sheet
Product Leaflet 3 pages · 302 KB · ZHERLEADA (apalutamide) is an androgen‑receptor inhibitor for treating metastatic castration‑sensitive and non‑metastatic castration‑resistant prostate…
Questions answered in ERLEADA manuals
What is the recommended dosage of ERLEADA?
The recommended dosage is 240 mg taken orally once a day.
What are the common side effects of ERLEADA?
Approximately 30 % of patients develop a rash, most of which resolve within two months; severe rash may require dose reduction or discontinuation.